Up-regulation of hERG K+ channels by B-RAF

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Pakladok, Tatsiana ^a   Hosseinzadeh, Zohreh ^a   Almilaji, Ahmad ^a   Lebedeva, Aleksandra ^a,b   Shumilina, Ekaterina ^a   Alesutan, Ioana ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELL MEMBRANE PROTEIN; CELL SURFACE PROTEIN; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; POTASSIUM CHANNEL HERG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOTINYLATION; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; NONHUMAN; OOCYTE; PATCH CLAMP TECHNIQUE; POTASSIUM CURRENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RHABDOMYOSARCOMA; SARCOMA CELL; UPREGULATION; VOLTAGE CLAMP TECHNIQUE; XENOPUS;

ANIMALS; ETHER-A-GO-GO POTASSIUM CHANNELS; FLOW CYTOMETRY; HUMANS; INDOLES; LUMINESCENT MEASUREMENTS; MICROSCOPY, CONFOCAL; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; UP-REGULATION; XENOPUS;

EID: 84900308772     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087457     Document Type: Article

References (61)

1. Sanguinetti MC (1999) Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann N Y Acad Sci 868: 406-413.
2. Vincent GM (1998) The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 49: 263-274.
3. Sanguinetti MC, Jurkiewicz NK (1990) Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96: 195-215. (Pubitemid 20227082)
4. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, et al. (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795-803.
5. Asher V, Sowter H, Shaw R, Bali A, Khan R (2010) Eag and HERG potassium channels as novel therapeutic targets in cancer. World J Surg Oncol 8: 113.
6. Pillozzi S, Arcangeli A (2010) Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv Exp Med Biol 674: 55-67.
7. Arcangeli A, Rosati B, Crociani O, Cherubini A, Fontana L, et al. (1999) Modulation of HERG current and herg gene expression during retinoic acid treatment of human neuroblastoma cells: potentiating effects of BDNF. J Neurobiol 40: 214-225. (Pubitemid 29343305)
8. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, et al. (2005) hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 93: 781-792. (Pubitemid 41486438)
9. Glassmeier G, Hempel K, Wulfsen I, Bauer CK, Schumacher U, et al. (2012) Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells. Pflugers Arch 463: 365-376.
10. Ouadid-Ahidouch H, Ahidouch A (2013) K(+) channels and cell cycle progression in tumor cells. Front Physiol 4: 220.
11. Jehle J, Schweizer PA, Katus HA, Thomas D (2011) Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis 2: e193.
12. Li H, Du YM, Guo L, Jie S, Zhang S, et al. (2009) The role of hERG1 K+ channels and a functional link between hERG1 K+ channels and SDF-1 in acute leukemic cell migration. Exp Cell Res 315: 2256-2264.
13. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, et al. (2007) VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110: 1238-1250. (Pubitemid 47281422)
14. Raschi E, Vasina V, Poluzzi E, De Ponti F (2008) The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res 57: 181-195.
15. Zheng F, Li H, Liang K, Du Y, Guo D, et al. (2012) Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia. Med Oncol 29: 2127-2135.
16. Li G, Hu Z, Yin H, Zhang Y, Huang X, et al. (2013) A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-a-go-go-related gene silencing in anaplastic thyroid carcinoma cells. Int J Nanomedicine 8: 1293-1306.
17. Zhang DY, Wang Y, Lau CP, Tse HF, Li GR (2008) Both EGFR kinase and Src-related tyrosine kinases regulate human ether-a-go-go-related gene potassium channels. Cell Signal 20: 1815-1821.
18. Borowiec AS, Hague F, Gouilleux-Gruart V, Lassoued K, Ouadid-Ahidouch H (2011) Regulation of IGF-1-dependent cyclin D1 and E expression by hEag1 channels in MCF-7 cells: the critical role of hEag1 channels in G1 phase progression. Biochim Biophys Acta 1813: 723-730.
19. Sisko JT, Tucker TJ, Bilodeau MT, Buser CA, Ciecko PA, et al. (2006) Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorg Med Chem Lett 16: 1146-1150. (Pubitemid 43142980)
20. Asghar U, Hawkes E, Cunningham D (2010) Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 9: 274-281.
21. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
22. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N (2012) The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16 Suppl 2: S17-27.
23. Kamata T, Pritchard C (2011) Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res 1: 955-971.
24. Roring M, Brummer T (2012) Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside. Crit Rev Oncog 17: 97-121.
25. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, et al. (2011) Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 129: 2297-2303.
26. Fuchs O (2013) Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets 13: 16-34.
27. Maier G, Palmada M, Rajamanickam J, Shumilina E, Bohmer C, et al. (2006) Upregulation of HERG channels by the serum and glucocorticoid inducible kinase isoform SGK3. Cell Physiol Biochem 18: 177-186. (Pubitemid 44946974)
28. Huang FD, Chen J, Lin M, Keating MT, Sanguinetti MC (2001) Long-QT syndrome-associated missense mutations in the pore helix of the HERG potassium channel. Circulation 104: 1071-1075. (Pubitemid 32803887)
29. Pakladok T, Hosseinzadeh Z, Alesutan I, Lang F (2012) Stimulation of the Na (+)-coupled glucose transporter SGLT1 by B-RAF. Biochem Biophys Res Commun 427: 689-693.
30. Alesutan I, Sopjani M, Dermaku-Sopjani M, Munoz C, Voelkl J, et al. (2012) Upregulation of Na-coupled glucose transporter SGLT1 by Tau tubulin kinase 2. Cell Physiol Biochem 30: 458-465.
31. Pathare G, Foller M, Daryadel A, Mutig K, Bogatikov E, et al. (2012) OSR1-Sensitive Renal Tubular Phosphate Reabsorption. Kidney Blood Press Res 36: 149-161.
32. Broer S, Broer A, Hamprecht B (1994) Expression of Na+-independent isoleucine transport activity from rat brain in Xenopus laevis oocytes. Biochim Biophys Acta 1192: 95-100. (Pubitemid 24171546)
33. Henrion U, Zumhagen S, Steinke K, Strutz-Seebohm N, Stallmeyer B, et al. (2012) Overlapping cardiac phenotype associated with a familial mutation in the voltage sensor of the KCNQ1 channel. Cell Physiol Biochem 29: 809-818.
34. Hosseinzadeh Z, Bhavsar SK, Lang F (2012) Downregulation of ClC-2 by JAK2. Cell Physiol Biochem 29: 737-742.
35. Hosseinzadeh Z, Bhavsar SK, Lang F (2012) Down-regulation of the myoinositol transporter SMIT by JAK2. Cell Physiol Biochem 30: 1473-1480.
36. Strutz-Seebohm N, Pusch M, Wolf S, Stoll R, Tapken D, et al. (2011) Structural basis of slow activation gating in the cardiac I Ks channel complex. Cell Physiol Biochem 27: 443-452.
37. Bogatikov E, Munoz C, Pakladok T, Alesutan I, Shojaiefard M, et al. (2012) Up-Regulation of Amino Acid Transporter SLC6A19 Activity and Surface Protein Abundance by PKB/Akt and PIKfyve. Cell Physiol Biochem 30: 1538-1546.
38. Hosseinzadeh Z, Bhavsar SK, Sopjani M, Alesutan I, Saxena A, et al. (2011) Regulation of the Glutamate Transporters by JAK2. Cellular Physiology and Biochemistry 28: 693-702.
39. Dermaku-Sopjani M, Sopjani M, Saxena A, Shojaiefard M, Bogatikov E, et al. (2011) Downregulation of NaPi-IIa and NaPi-IIb Na+-coupled Phosphate Transporters by Coexpression of Klotho. Cellular Physiology and Biochemistry 28: 251-258.
40. Hosseinzadeh Z, Dong L, Bhavsar SK, Warsi J, Almilaji A, et al. (2013) Upregulation of peptide transporters PEPT1 and PEPT2 by Janus kinase JAK2. Cell Physiol Biochem 31: 673-682.
41. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85-100. (Pubitemid 11012976)
42. Almilaji A, Szteyn K, Fein E, Pakladok T, Munoz C, et al. (2013) Downregulation of Na/K+ atpase activity by human parvovirus B19 capsid protein VP1. Cell Physiol Biochem 31: 638-648.
43. Szteyn K, Schmid E, Nurbaeva MK, Yang W, Munzer P, et al. (2012) Expression and functional significance of the Ca(2+)-activated Cl(-) channel ANO6 in dendritic cells. Cell Physiol Biochem 30: 1319-1332.
44. Mia S, Munoz C, Pakladok T, Siraskar G, Voelkl J, et al. (2012) Downregulation of Kv1.5 K channels by the AMP-activated protein kinase. Cell Physiol Biochem 30: 1039-1050.
45. Schmid E, Bhandaru M, Nurbaeva MK, Yang W, Szteyn K, et al. (2012) SGK3 regulates Ca(2+) entry and migration of dendritic cells. Cell Physiol Biochem 30: 1423-1435.
46. Barry PH, Lynch JW (1991) Liquid junction potentials and small cell effects in patch-clamp analysis. J Membr Biol 121: 101-117.
47. Bianchi L, Wible B, Arcangeli A, Taglialatela M, Morra F, et al. (1998) herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res 58: 815-822. (Pubitemid 28099497)
48. Almilaji A, Munoz C, Elvira B, Fajol A, Pakladok T, et al. (2013) AMP-activated protein kinase regulates hERG potassium channel. Pflugers Arch in press.
49. Lamothe SM, Zhang S (2013) The serum- and glucocorticoid-inducible kinases SGK1 and SGK3 regulate hERG channel expression via ubiquitin ligase Nedd4-2 and GTPase Rab11. J Biol Chem 288: 15075-15084.
50. Cui Z, Zhang S (2013) Regulation of the human ether-a-go-go-related gene (hERG) channel by Rab4 protein through neural precursor cell-expressed developmentally down-regulated protein 4-2 (Nedd4-2). J Biol Chem 288: 21876-21886.
51. Guo J, Wang T, Li X, Shallow H, Yang T, et al. (2012) Cell surface expression of human ether-a-go-go-related gene (hERG) channels is regulated by caveolin-3 protein via the ubiquitin ligase Nedd4-2. J Biol Chem 287: 33132-33141.
52. Pakladok T, Almilaji A, Munoz C, Alesutan I, Lang F (2013) PIKfyve Sensitivity of hERG Channels. Cell Physiol Biochem 31: 785-794.
53. Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, et al. (2012) hERG K(+) channels: structure, function, and clinical significance. Physiol Rev 92: 1393-1478.
54. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, et al. (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66: 33-44. (Pubitemid 38822085)
55. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, et al. (2005) Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145: 15-23. (Pubitemid 40675544)
56. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, et al. (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-323. (Pubitemid 40096484)
57. Guo J, Massaeli H, Li W, Xu J, Luo T, et al. (2007) Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 321: 911-920. (Pubitemid 46762679)
58. Ficker E, Obejero-Paz CA, Zhao S, Brown AM (2002) The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem 277: 4989-4998. (Pubitemid 34968538)
59. Zhou Z, Gong Q, January CT (1999) Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem 274: 31123-31126.
60. Muslin AJ (2005) Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med 15: 225-229.
61. Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, et al. (2011) A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res 109: 1401-1409.